2 unknown, 1 active not recruiting, 1 not yet recruiting. 4 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 4 | Unknown 2, Active not recruiting 1, Not yet recruiting 1 |
| Phase 2 | 3 | Unknown 2, Not yet recruiting 1 |
Follow Immune Checkpoint Inhibitors: new trials by email Literature Review of Immune Checkpoint Inhibitors trials Research Report on Immune Checkpoint Inhibitors
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy and Safety of Immune Checkpoint Inhibitors for Refractory Opportunistic Infections in AIDS Sintilimab - HIV, AIDS | Phase 1 / Phase 2 | Not yet recruiting | Shanghai Public Health Clinical Center | 50 | 2026-05-01 | 2026-05-12 |
| Cadonilimab in the Treatment of Recurrent/Metastatic Nasopharyngeal Carcinoma Cadonilimab, Gemcitabine, Cisplatin - Nasopharyngeal Carcinoma, Immune Checkpoint Inhibitors | Phase 1 / Phase 2 | Unknown | Guangxi Medical University | 20 | 2023-08-01 | 2023-06-12 |
| Efficacy and Safety of SBRT Combined With Cardonilizumab and Lenvastinib in the Treatment of Unresectable Hepatocellular Carcinoma With Portal Vein Tumor Thrombus Cadonilimab, Stereotactic radiotherapy, Renvatinib - Hepatocellular Carcinoma Non-resectable, Portal Vein Tumor Thrombus | Phase 1 / Phase 2 | Unknown | First Affiliated Hospital of Guangxi Medical University | 30 | 2023-02-02 | 2023-09-15 |
| Safety of SBRT With Anti-PD1 and Anti-IL-8 for the Treatment of Multiple Metastases in Advanced Solid Tumors and Melanoma nivolumab, BMS-986253, Stereotactic Body Radiotherapy (SBRT) - Melanoma, Unresectable Solid Tumors | Phase 1 | Active not recruiting | Yana Najjar | 50 | 2021-11-29 | 2026-08-20 |
Acquired Immunodeficiency Syndrome (1) · Carcinoma, Hepatocellular (1) · Melanoma (1) · Nasopharyngeal Carcinoma (1) · Neoplasms (1) · Neoplasms by Histologic Type (1) · Neoplasms by Site (1) · Opportunistic Infections (1)
Carcinoma (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms by Site (2) · Neoplasms, Glandular and Epithelial (2) · Adenocarcinoma (1) · Blood-Borne Infections (1) · Communicable Diseases (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Genital Diseases (1) · HIV Infections (1) · Head and Neck Neoplasms (1) · Immune System Diseases (1) · Immunologic Deficiency Syndromes (1)
Radiosurgery (2) · Cisplatin (1) · Gemcitabine (1) · HuMax-IL8 (1) · Nivolumab (1) · sintilimab (1) · spartalizumab (1)
First Affiliated Hospital of Guangxi Medical University (1) · Guangxi Medical University (1) · Shanghai Public Health Clinical Center (1) · Yana Najjar (1)
China (2) · United States (1)